<DOC>
	<DOCNO>NCT00475423</DOCNO>
	<brief_summary>This single arm study evaluate efficacy safety MabThera monotherapy patient refractory , relapse chronic idiopathic thrombocytopenic purpura ( ITP ) . Patients receive infusion MabThera 1000mg i.v . day 1 15 . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Patients With Idiopathic Thrombocytopenic Purpura .</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; refractory , relapse chronic idiopathic thrombocytopenic purpura ; stable therapy 3 week prior study entry . newly diagnose ITP ( &lt; 6 week ) ; prior treatment MabThera ; active bleeding require platelet transfusion within 7 day prior entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>